butyrate glp-1 Mode of action of SCFAs: (A) activation of GPR41 and GPR43 boosts the Butyrate to combat obesity and

For example, a case report showed that a 24-week course of liraglutide in a 62-year-old male with HIV, obesity, type 2 diabetes, and moderate OSA managed with CPAP reduced his AHI from 27 to 7.1

In February 2026, full results from the REDEFINE 2 study showed CagriSema achieving 23% weight loss at 84 weeks but falling short of its primary endpoint under the treatment policy estimand (which measures efficacy across all patients regardless of whether they completed treatment, rather than only those who remained on it)

Whether you're cutting, recomposing, or just taking back controlGLP-1X was built to shift your internal state from reactive to resilient

2025, she shared another photo of her slimmer physique thanks to Mounjaro